An Overview on the Role of α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to Therapeutics

E-ISSN： 1996-3181|15|10|1240-1252

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.15, Iss.10, 2016-12, pp. : 1240-1252

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Strategic Selection of Neuroinflammatory Models in Parkinson's Disease: Evidence from Experimental Studies

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 5, 2013-08 ,pp. : 680-697

Bentham Science Publishers

Access to resources Recommend Favorite

Animal Models for Parkinson's Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 9, 2014-11 ,pp. : 1580-1594

Bentham Science Publishers

Access to resources Recommend Favorite

-Synuclein Ubiquitination and Novel Therapeutic Targets for Parkinson’s Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 4, 2014-06 ,pp. : 630-637

Bentham Science Publishers

Access to resources Recommend Favorite

Parkinson’s Disease: Alpha Synuclein, Heme Oxygenase and Biotherapeutic Countermeasures

Current Pharmaceutical Design, Vol. 24, Iss. 20, 2018-06 ,pp. : 2317-2321

Bentham Science Publishers

Access to resources Recommend Favorite

-Synuclein- and MPTP-Generated Rodent Models of Parkinson's Disease and the Study of Extracellular Striatal Dopamine Dynamics: A Microdialysis Approach

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 9, Iss. 4, 2010-08 ,pp. : 482-490

Bentham Science Publishers

Access to resources Recommend Favorite